Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 1, 2013, Pages 45-52

  Liao, Katherine P ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

C reactive protein; Cardiovascular disease; Coronary artery disease; Coronary heart disease; Framingham risk score calculator; Hypertension; Inflammation; Reynolds risk score calculator; Rheumatoid arthritis; Traditional cardiovascular risk factors

Indexed keywords

ADALIMUMAB; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LOW DENSITY LIPOPROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; COVARIANCE; DIABETES MELLITUS; DYSLIPIDEMIA; FRAMINGHAM RISK SCORE; HUMAN; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; REYNOLDS RISK SCORE; RHEUMATOID ARTHRITIS; SMOKING;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; OBESITY; PREVALENCE; RISK FACTORS; SMOKING;

EID: 84871147265     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes243     Document Type: Review

References (88)

1. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44, 2737-45.
2. Solomon DH, Kremer J, Curtis JR et al. Explaining the cardiovascular risk associated with rheumatoid arthritis, traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010, 69, 1920-5.
3. Gonzalez A, Maradit Kremers H, Crowson CS et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008, 67, 64-9.
4. Brady SR, de Courten B, Reid CM et al. The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol 2009, 36, 34-40.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320, 915-24.
6. NCEP. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report), National Heart, Blood, Lung Institute, 2002 http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm (29 August 2012, date last accessed).
7. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis, a meta-analysis. Joint Bone Spine 2012, 78, 179-83.
8. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97, 1837-47.
9. van Halm VP, Nielen MM, Nurmohamed MT et al. Lipids and inflammation, serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007, 66, 184-8.
10. Myasoedova E, Crowson CS, Kremers HM et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010, 69, 1310-4.
11. Myasoedova E, Crowson CS, Kremers HM et al. Lipid paradox in rheumatoid arthritis, the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011, 70, 482-7.
12. Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010, 29, 947-55.
13. Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006, 35, 107-11.
14. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24, 83-6.
15. Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007, 66, 958-61.
16. Popa C, van den Hoogen FH, Radstake TR et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007, 66, 1503-7.
17. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006, 1069, 414-9.
18. Soubrier M, Jouanel P, Mathieu S et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008, 75, 22-4.
19. Spanakis E, Sidiropoulos P, Papadakis J et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006, 33, 2440-6.
20. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007, 26, 1495-8.
21. Vis M, Nurmohamed MT, Wolbink G et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005, 32, 252-5.
22. Kiortsis DN, Mavridis AK, Filippatos TD et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006, 33, 921-3.
23. Jamnitski A, Visman IM, Peters MJ et al. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis, the ETRA study. Ann Rheum Dis 2010, 69, 1929-33.
24. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis, a Cochrane systematic review. J Rheumatol 2011, 38, 10-20.
25. Hospital OU. Effect of the interleukin-6 receptor antagonist tocilizumab in non-ST elevation myocardial infarction. ClinicalTrials.gov. [cited 26 April 2012], http://clinicaltrials.gov/show/NCT01491074 (12 December 2012, date last accessed).
26. Roche H-L. A study of the effect of tocilizumab on markers of atherogenic risk in patients with moderate to severe rheumatoid arthritis. ClinicalTrials.gov.[cited 26 April 2012] http://clinicaltrials.gov/show/NCT00535782 (7 December 2012, date last accessed).
27. Westlake SL, Colebatch AN, Baird J et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis, a systematic literature review. Rheumatology 2010, 49, 295-307.
28. Morris SJ, Wasko MC, Antohe JL et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res 2011, 63, 530-4.
29. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease, reversal ofdeleterious effects of steroids on lipids. Am J Med 1990, 89, 322-6.
30. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. J Rheumatol 2005, 32, 2311-6.
31. Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995, 96, 2758-67.
32. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states, proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008, 10, 213.
33. McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA), double-blind, randomised placebo-controlled trial. Lancet 2004, 363, 2015-21.
34. Reilly MP, Wolfe ML, Rhodes T et al. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004, 110, 803-9.
35. Chung CP, Oeser A, Solus JF et al. Inflammation-associated insulin resistance, differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008, 58, 2105-12.
36. Cheal KL, Abbasi F, Lamendola C et al. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004, 53, 1195-200.
37. Dessein PH, Joffe BI, Stanwix AE. Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid 2004, 14, 443-6.
38. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006, 54, 2765-75.
39. Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010, 69, 2114-7.
40. Han C, Robinson DW Jr, Hackett MV et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006, 33, 2167-72.
41. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44, 2737-45.
42. Chung CP, Oeser A, Solus JF et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008, 196, 756-63.
43. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis, a pilot study. Arthritis Res 2002, 4, R12.
44. Simard JF, Mittleman MA. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol 2007, 34, 469-73.
45. Liao KP, Gunnarsson M, Kallberg H et al. Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum 2009, 60, 653-60.
46. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107, 1303-7.
47. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005, 64, 765-6.
48. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis, effect of anti-TNFalpha therapy. Scand J Rheumatol 2007, 36, 91-6.
49. Schultz O, Oberhauser F, Saech J et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PloS one 2010, 5, e14328.
50. Solomon DH, Massarotti E, Garg R et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 22, 305, 2525-31.
51. Wasko MC, Hubert HB, Lingala VB et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007, 298, 187-93.
52. CDC. Prevalence of obesity among adults with arthritis-United States, 2003-2009. MMWR Morb Mortal Wkly Rep 60, 509-13.
53. WHO. BMI classification Global Database on Body Mass Index 2006 [cited 13 April 2012], http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.
54. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD. Obesity in rheumatoid arthritis. Rheumatology 2011, 50, 450-62.
55. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis 1972, 25, 329-43.
56. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007, 66, 1316-21.
57. Giles JT, Allison M, Blumenthal RS et al. Abdominal adiposity in rheumatoid arthritis, association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 62, 3173-82.
58. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation, The ATTICA study. Atherosclerosis 2005, 183, 308-15.
59. McGuire TR, Brusnahan SK, Bilek LD et al. Inflammation associated with obesity, relationship with blood and bone marrow endothelial cells. Obesity 2011, 19, 2130-6.
60. Wisse BE. The inflammatory syndrome, the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004, 15, 2792-800.
61. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282, 2131-5.
62. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women, the Reynolds Risk Score. JAMA 2007, 297, 611-9.
63. Giles JT, Bartlett SJ, Andersen R et al. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum 2008, 58, 2632-41.
64. Giles JT, Allison M, Blumenthal RS et al. Abdominal adiposity in rheumatoid arthritis, association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010, 62, 3173-82.
65. McEntegart A, Capell HA, Creran D et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001, 40, 640-4.
66. Maki-Petaja KM, Hall FC, Booth AD et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006, 114, 1185-92.
67. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis, results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009, 60, 1895-905.
68. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005, 165, 490-6.
69. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121, 289-300.
70. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153, 477-84.
71. Mazzantini M, Talarico R, Doveri M et al. Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids, a retrospective study. J Rheumatol 2010, 37, 2232-6.
72. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006, 119, 503 e1-9.
73. Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993, 20, 1830-5.
74. Yang Q, Cogswell ME, Flanders WD et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA 2012, 307, 1273-83.
75. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107, 1303-7.
76. Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 2001, 31, 146-59.
77. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000, 27, 630-7.
78. van den Berg MH, de Boer IG, le Cessie S, Breedveld FC, Vliet Vlieland TP. Are patients with rheumatoid arthritis less physically active than the general population? J Clin Rheumatol 2007, 13, 181-6.
79. Mancuso CA, Rincon M, Sayles W, Paget SA. Comparison of energy expenditure from lifestyle physical activities between patients with rheumatoid arthritis and healthy controls. Arthritis Rheum 2007, 57, 672-8.
80. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF et al. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009, 16, 188-94.
81. Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ et al. Rheumatoid arthritis, cardiovascular disease and physical exercise, a systematic review. Rheumatology 2008, 47, 239-48.
82. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores, results of a multiple ethnic groups investigation. JAMA 2001, 286, 180-7.
83. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe, the SCORE project. Eur Heart J 2003, 24, 987-1003.
84. Chung CP, Oeser A, Avalos I et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006, 8, R186.
85. Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012, 110, 420-4.
86. Iannaccone CK, Lee YC, Cui J et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy, data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology 2011, 50, 40-6.
87. Del Rincon I, Williams K, Stern MP et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003, 48, 1833-40.
88. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69, 325-31.